Effect of age, gender, and performance status (PS) on the duration results of adjuvant chemotherapy for stage III colon cancer: The IDEA collaboration.
Anthony F. Shields(Wayne State University), Timothy Iveson(University Hospital Southampton NHS Foundation Trust), Valter Torri(Istituti di Ricovero e Cura a Carattere Scientifico), Ioannis Boukovinas, Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Jeffrey A. Meyerhardt(CancerCare), James Paul(Cancer Research UK), Qian Shi(Mayo Clinic), Axel Grothey(Campbell Clinic), Takayuki Yoshino(University of Tsukuba), Fang‐Shu Ou(Mayo Clinic), Thierry André(Inserm), Ioannis Souglakos(University of Crete), Roberto Labianca(Ospedale Papa Giovanni XXIII), Alberto F. Sobrero(Ospedale Policlinico San Martino), Takeshi Kato(Osaka National Hospital), Déwi Vernerey(Inserm), Takeharu Yamanaka(National Cancer Center Hospital East), Stylianos Kakolyris(University Hospital of Alexandroupolis), Rachel Kerr(Cancer Research UK Clinical Trials Unit)
Cited by 6
Related Papers
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
|New England Journal of Medicine|2020|2.9k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k